mrna-1195
Vaccineexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 5, 2023 (NCT05831111)
Timeline
Indications
Mechanism of action
- epstein-barr virusImmunity, active
epstein-barr virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06735248 | Phase 2 | Dec 31, 2024 | Moderna Therapeutics |
| NCT05831111 | Phase 1 | Apr 5, 2023 | Moderna Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Moderna Therapeutics | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1